• LAST PRICE
    38.9100
  • TODAY'S CHANGE (%)
    Trending Down-1.5100 (-3.7358%)
  • Bid / Lots
    38.8900/ 2
  • Ask / Lots
    38.9500/ 1
  • Open / Previous Close
    40.3500 / 40.4200
  • Day Range
    Low 38.7500
    High 40.6600
  • 52 Week Range
    Low 27.9850
    High 50.9900
  • Volume
    275,608
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 40.42
TimeVolumeXENE
09:32 ET103540.35
09:34 ET40040.38
09:45 ET50040.66
09:50 ET40040.605
09:57 ET28240.53
09:59 ET10040.51
10:01 ET28040.54
10:03 ET30340.47
10:06 ET60040.505
10:08 ET20040.41
10:10 ET10040.3
10:14 ET10040.45
10:15 ET50540.41
10:26 ET10040.33
10:28 ET10040.47
10:32 ET22840.411
10:42 ET10040.4
10:44 ET70040.32
10:48 ET40040.22
10:55 ET40340.23
10:57 ET10040.23
11:00 ET99340.27
11:02 ET70040.36
11:04 ET70040.27
11:06 ET122040.12
11:09 ET10040.16
11:11 ET120040.08
11:22 ET151239.99
11:24 ET140039.9
11:27 ET20039.88
11:29 ET10039.935
11:36 ET314739.915
11:38 ET10040.02
11:42 ET20039.93
11:44 ET30039.91
11:45 ET10839.96
11:49 ET30039.8
11:54 ET10039.95
11:56 ET10039.96
12:05 ET40039.91
12:07 ET60039.83
12:09 ET54139.85
12:12 ET510039.92
12:16 ET50039.86
12:18 ET161740.06
12:20 ET10039.94
12:23 ET113939.91
12:27 ET17539.8821
12:32 ET40040.03
12:38 ET10040.03
12:45 ET20040.01
12:54 ET50039.93
12:57 ET215039.8
12:59 ET33439.86
01:01 ET60039.8
01:06 ET3044039.71
01:10 ET110039.62
01:12 ET30039.57
01:14 ET10039.545
01:19 ET20039.47
01:21 ET10039.465
01:28 ET20039.47
01:32 ET205639.425
01:33 ET30039.39
01:35 ET70039.42
01:37 ET10039.42
01:42 ET10039.44
01:44 ET170439.551
01:46 ET10039.565
01:48 ET50039.505
01:55 ET10039.535
01:57 ET10039.52
02:00 ET4089039.55
02:02 ET1775239.48
02:04 ET210039.72
02:06 ET20039.735
02:08 ET260039.74
02:09 ET55739.68
02:15 ET10039.655
02:18 ET10039.655
02:20 ET70039.55
02:22 ET30039.53
02:24 ET2459239.49
02:27 ET10039.53
02:31 ET20739.505
02:33 ET10039.5325
02:36 ET30039.535
02:38 ET175739.34
02:40 ET1286939.41
02:42 ET1080039.34
02:44 ET20039.365
02:45 ET189339.365
02:47 ET50039.365
02:49 ET20039.35
02:51 ET165639.25
02:54 ET20039.24
02:56 ET30039.275
02:58 ET10039.24
03:00 ET30039.22
03:02 ET10039.295
03:03 ET112639.31
03:05 ET10039.325
03:12 ET40739.27
03:14 ET99239.22
03:18 ET277439.08
03:20 ET90038.98
03:23 ET10038.94
03:25 ET20038.985
03:27 ET130138.89
03:30 ET70038.89
03:32 ET10038.905
03:34 ET69738.84
03:36 ET20038.85
03:38 ET50038.835
03:39 ET110038.88
03:41 ET100838.97
03:43 ET90038.9
03:45 ET50038.93
03:48 ET88338.885
03:50 ET403338.83
03:52 ET233839.015
03:54 ET355738.94
03:56 ET190038.91
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXENE
Xenon Pharmaceuticals Inc
3.1B
-14.3x
---
United StatesAPGE
Apogee Therapeutics Inc
3.1B
-24.2x
---
United StatesDYN
Dyne Therapeutics Inc
3.1B
-8.2x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesSWTX
SpringWorks Therapeutics Inc
3.1B
-8.3x
---
United StatesSMMT
Summit Therapeutics Inc
3.2B
-26.6x
---
As of 2024-05-21

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

Chairman of the Board
Simon Pimstone
President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.1B
Revenue (TTM)
$0.00
Shares Outstanding
75.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.23
EPS
$-2.71
Book Value
$12.31
P/E Ratio
-14.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.